Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
about
A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.Renal Drug Transporters and Drug Interactions.Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake.Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
P2860
Q37588842-41B7E380-C00A-4CFF-BA01-7B18AAEF5EF5Q38990518-A00C30B7-4E18-4FE5-81E7-980D5859C230Q39140289-3BB68A29-4FEA-464D-882C-1C03AC9943EFQ39231122-6E0EC2C0-C2A2-4DDE-9D6B-090930B9FB2CQ40622094-36238961-1117-4F0F-A185-21CB8514FC44Q42206175-77E3C6E2-34F6-4A4D-A1CF-225B0C1229A4Q42696416-61E0A964-E907-4163-B13A-D60AD5DF5A88Q47260852-DD144A4B-4CE9-4D1A-B153-1993D3677A23Q51692185-C498368A-E2ED-49DD-8BCA-38E9F38782BCQ54119005-8FFF1857-D27E-4D4C-9331-7E9D08BE3CCF
P2860
Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical Pharmacokinetic, Phar ...... se Co-transporter 2 Inhibitor.
@en
type
label
Clinical Pharmacokinetic, Phar ...... se Co-transporter 2 Inhibitor.
@en
prefLabel
Clinical Pharmacokinetic, Phar ...... se Co-transporter 2 Inhibitor.
@en
P2860
P1476
Clinical Pharmacokinetic, Phar ...... se Co-transporter 2 Inhibitor.
@en
P2093
Damayanthi Devineni
David Polidori
P2860
P2888
P304
P356
10.1007/S40262-015-0285-Z
P577
2015-06-04T00:00:00Z
P6179
1010177749